← Back to Search

Brain Stimulation

Brain Stimulation for Severe Treatment-Resistant Depression

N/A
Recruiting
Led By Ziad Nahas, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether electrical stimulation of the surface of the brain can help treat depression. participants receive intermittent electrical stimulation to the brain. It is still experimental.

Who is the study for?
This trial is for adults with severe, treatment-resistant depression who have not responded to multiple antidepressant treatments and are under a psychiatrist's care. They must be able to consent, complete necessary evaluations, and have support within a 30-minute drive. Excluded are those with recent suicide attempts or high risk of suicide, active drug use, pregnancy, certain mental health conditions like schizophrenia or psychotic features in their depression.
What is being tested?
The study tests Prefrontal Cortical Stimulation (PCS) using the Proclaim Elite SCS System by Abbott Laboratories. This involves surgical placement of electrical leads on the brain surface behind the forehead to stimulate it intermittently. Although FDA-approved for other conditions like chronic pain and Parkinson's disease, its effectiveness for depression is still being investigated.
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site, headache, infection risk from surgery, seizures (especially if there's a history), mood changes due to brain stimulation and possible interference with thinking or memory.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in LPP Amplitude
Secondary study objectives
Change in HRSD Scores

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Prefrontal Cortical Stimulation (PCS)Experimental Treatment1 Intervention
Stereotactically implanted bilateral PCS

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor
1,439 Previous Clinical Trials
1,621,943 Total Patients Enrolled
Ziad Nahas, MDPrincipal InvestigatorUniversity of Minnesota
2 Previous Clinical Trials
37 Total Patients Enrolled

Media Library

Epidural Prefrontal Cortical Stimulation (EpCS) (Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04124341 — N/A
Major Depressive Disorder Research Study Groups: Prefrontal Cortical Stimulation (PCS)
Major Depressive Disorder Clinical Trial 2023: Epidural Prefrontal Cortical Stimulation (EpCS) Highlights & Side Effects. Trial Name: NCT04124341 — N/A
Epidural Prefrontal Cortical Stimulation (EpCS) (Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04124341 — N/A
Major Depressive Disorder Patient Testimony for trial: Trial Name: NCT04124341 — N/A
~7 spots leftby Dec 2027